Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases

Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases

Patients with different autoimmune inflammatory diseases (AIID) on biological therapy are at risk of pneumococcal disease. Adults with inflammatory arthropathies, connective tissue diseases, psoriasis, or inflammatory bowel disease on biological therapy such as anti-TNFα, rituximab, tocilizumab, aba...

Full description

Bibliographic Details
Main Authors: Patricia Richi, Jose Yuste, Teresa Navío, Laura González-Hombrado, Marina Salido, Israel Thuissard-Vasallo, Ana Jiménez-Díaz, Jesús Llorente, Laura Cebrián, Leticia Lojo, Martina Steiner, Tatiana Cobo, María Dolores Martín, Marta García-Castro, Patricia Castro, Santiago Muñoz-Fernández
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Vaccines
Subjects:
PPV23
PCV13
OPKA titers
invasive pneumococcal disease
biological therapy
anti-TNFα
Online Access:https://www.mdpi.com/2076-393X/9/3/203

Internet

https://www.mdpi.com/2076-393X/9/3/203

Similar Items